Medications for Granulomatosis with Polyangiitis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Granulomatosis with Polyangiitis.
Found 4 Approved Drugs for Granulomatosis with Polyangiitis
RiTUXimab
Brand Names
Rituxan, Ruxience, Riabni, Rituxan Hycela, Truxima
RiTUXimab
Brand Names
Rituxan, Ruxience, Riabni, Rituxan Hycela, Truxima
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: November 26, 1997
Classification: CD20-directed Cytolytic Antibody
RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL).
Nucala
Generic Name
Mepolizumab
Nucala
Generic Name
Mepolizumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: November 04, 2015
Classification: Interleukin-5 Antagonist
NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype.
Fasenra
Generic Name
Benralizumab
Fasenra
Generic Name
Benralizumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: November 14, 2017
Classification: Interleukin-5 Receptor alpha-directed Cytolytic Antibody
FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype.
Tavneos
Generic Name
Avacopan
Tavneos
Generic Name
Avacopan
Form: Capsule
Method of administration: Oral
FDA approval date: October 18, 2021
Classification: Complement 5a Receptor Antagonist
TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. TAVNEOS is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. ( 1 )
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances